{"id":"pk101-002","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4303334","moleculeType":"Small molecule","molecularWeight":"612.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PK101-002 works by inhibiting the HIF-1α protein, which is involved in the regulation of cellular responses to hypoxia. This inhibition leads to a decrease in the production of angiogenic factors, resulting in anti-tumor effects.","oneSentence":"PK101-002 is a small molecule that targets the HIF-1α pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:10.949Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04858659","phase":"PHASE3","title":"A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis","status":"UNKNOWN","sponsor":"PMG Pharm Co., Ltd","startDate":"2021-05-20","conditions":"Knee Osteoarthritis","enrollment":354},{"nctId":"NCT03876210","phase":"PHASE1","title":"Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs","status":"COMPLETED","sponsor":"PMG Pharm Co., Ltd","startDate":"2019-07-12","conditions":"Arthritis","enrollment":47},{"nctId":"NCT03553316","phase":"PHASE1","title":"Drug-Drug Interaction Between PK101-001 and PK101-002","status":"COMPLETED","sponsor":"PMG Pharm Co., Ltd","startDate":"2019-02-28","conditions":"Arthritis","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["A"],"phase":"phase_3","status":"active","brandName":"PK101-002","genericName":"PK101-002","companyName":"PMG Pharm Co., Ltd","companyId":"pmg-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PK101-002 is a small molecule that targets the HIF-1α pathway. Used for Metastatic non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}